CN104146972A - 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 - Google Patents
罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 Download PDFInfo
- Publication number
- CN104146972A CN104146972A CN201410427391.5A CN201410427391A CN104146972A CN 104146972 A CN104146972 A CN 104146972A CN 201410427391 A CN201410427391 A CN 201410427391A CN 104146972 A CN104146972 A CN 104146972A
- Authority
- CN
- China
- Prior art keywords
- ropivacaine
- nanoparticle
- mass concentration
- preparation
- polylactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 title claims abstract description 139
- 229960001549 ropivacaine Drugs 0.000 title claims abstract description 139
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 103
- 238000002474 experimental method Methods 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000003513 alkali Substances 0.000 claims abstract description 22
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- 239000002244 precipitate Substances 0.000 claims abstract description 18
- 230000010494 opalescence Effects 0.000 claims abstract description 16
- 239000000725 suspension Substances 0.000 claims abstract description 16
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 238000001132 ultrasonic dispersion Methods 0.000 claims abstract description 11
- 238000005406 washing Methods 0.000 claims abstract description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000001704 evaporation Methods 0.000 claims abstract description 8
- 230000008020 evaporation Effects 0.000 claims abstract description 8
- 238000011160 research Methods 0.000 claims abstract description 8
- 208000035126 Facies Diseases 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 229920001400 block copolymer Polymers 0.000 claims description 23
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 23
- 239000004626 polylactic acid Substances 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 20
- 238000013461 design Methods 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000005457 optimization Methods 0.000 claims description 10
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 9
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 210000004087 cornea Anatomy 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000009533 lab test Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000011835 investigation Methods 0.000 claims description 3
- 235000019353 potassium silicate Nutrition 0.000 claims description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 2
- 230000003578 releasing effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 208000005298 acute pain Diseases 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 239000012074 organic phase Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000009777 vacuum freeze-drying Methods 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 15
- 238000012803 optimization experiment Methods 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
指标 | 预测值 | 实测值 | 偏差(%) |
包封率 | 79.28 | 74.82±2.53 | 5.06 |
载药量 | 14.84 | 13.81±1.35 | 6.73 |
粒径 | 332.1 | 331.21±2.11 | 0.31 |
OD | 1.02 | 0.98±0.21 | 3.9 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410427391.5A CN104146972B (zh) | 2014-08-27 | 2014-08-27 | 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410427391.5A CN104146972B (zh) | 2014-08-27 | 2014-08-27 | 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104146972A true CN104146972A (zh) | 2014-11-19 |
CN104146972B CN104146972B (zh) | 2017-01-18 |
Family
ID=51872741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410427391.5A Active CN104146972B (zh) | 2014-08-27 | 2014-08-27 | 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104146972B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036408A1 (zh) * | 2015-09-01 | 2017-03-09 | 四川海思科制药有限公司 | S-(-)-1-丙基-2',6'-二甲苯胺甲酰基哌啶晶体及其缓释制剂 |
CN107320710A (zh) * | 2017-07-10 | 2017-11-07 | 北华大学 | 脑蛋白水解物制剂及其设计方法 |
CN116585488A (zh) * | 2023-05-08 | 2023-08-15 | 广东省第二人民医院(广东省卫生应急医院) | 一种罗哌卡因纳米载药材料及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032398A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for drug delivery |
CN101961316A (zh) * | 2010-09-20 | 2011-02-02 | 中国人民解放军第三军医大学 | 一种lid-peg-plga缓释纳米微球及其制备方法 |
-
2014
- 2014-08-27 CN CN201410427391.5A patent/CN104146972B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032398A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for drug delivery |
CN101961316A (zh) * | 2010-09-20 | 2011-02-02 | 中国人民解放军第三军医大学 | 一种lid-peg-plga缓释纳米微球及其制备方法 |
Non-Patent Citations (8)
Title |
---|
CAROLINA MORALES MORAES ET AL.: "Initial Development and Characterization of PLGA Nanospheres Containing Ropivacaine", 《J BIOL PHYS》, vol. 33, 31 December 2007 (2007-12-31) * |
XAVIER GARCIA ET AL.: "In vitro characterization and in vivo analgesic and anti-allodynic activity of PLGA-bupivacaine nanoparticles", 《J NANOPART RES》, vol. 13, 31 December 2011 (2011-12-31) * |
张文彤 等: "《世界优秀统计工具SPSS 11.0统计分析教程(高级篇)》", 30 June 2002, article "星点设计" * |
杭太俊: "《药物分析》", 31 August 2011 * |
梅兴国: "《微载体药物递送系统》", 30 November 2009 * |
梅兴国: "《药物新机型与制剂新技术》", 31 January 2007, article "微粒载体给药系统新机型与新技术" * |
盛欢欢等: "星点设计-效应面法优化穿心莲总内酯固体脂质纳米粒处方", 《中成药》, vol. 34, no. 8, 31 August 2012 (2012-08-31) * |
高志贤等: "《纳米生物医药》", 30 April 2007, article "第八章"2.超声乳化法"" * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036408A1 (zh) * | 2015-09-01 | 2017-03-09 | 四川海思科制药有限公司 | S-(-)-1-丙基-2',6'-二甲苯胺甲酰基哌啶晶体及其缓释制剂 |
CN107848973A (zh) * | 2015-09-01 | 2018-03-27 | 四川海思科制药有限公司 | S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂 |
CN107320710A (zh) * | 2017-07-10 | 2017-11-07 | 北华大学 | 脑蛋白水解物制剂及其设计方法 |
CN107320710B (zh) * | 2017-07-10 | 2020-11-06 | 北华大学 | 脑蛋白水解物制剂及其设计方法 |
CN116585488A (zh) * | 2023-05-08 | 2023-08-15 | 广东省第二人民医院(广东省卫生应急医院) | 一种罗哌卡因纳米载药材料及其制备方法 |
CN116585488B (zh) * | 2023-05-08 | 2024-02-23 | 广东省第二人民医院(广东省卫生应急医院) | 一种罗哌卡因纳米载药材料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104146972B (zh) | 2017-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pallagi et al. | Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation | |
Cao et al. | In vitro release and in vitro–in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles | |
Srinivas et al. | Preparation and evaluation of niosomes containing aceclofenac | |
Gulati et al. | Intranasal delivery of chitosan nanoparticles for migraine therapy | |
Garcia et al. | Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications | |
CN103860584B (zh) | 一种奥美拉唑碳酸氢钠胶囊的制作方法 | |
Verma et al. | Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide | |
Bagger et al. | The potential of nasal application for delivery to the central brain—a microdialysis study of fluorescein in rats | |
Lee et al. | A nanohybrid system for taste masking of sildenafil | |
CN104146972A (zh) | 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法 | |
Fang et al. | Characterizing the release mechanism of donepezil-loaded PLGA microspheres in vitro and in vivo | |
Qian et al. | Drug-rich phases induced by amorphous solid dispersion: arbitrary or intentional goal in oral drug delivery? | |
BR112015017246B1 (pt) | Composição farmacêutica aquosa injetável, seu uso e seringa | |
Salem et al. | Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler | |
Miller et al. | Nanoparticle deposition onto biofilms | |
CN106924172A (zh) | 一种石杉碱甲溶致液晶制剂及其制备方法 | |
CN113081959A (zh) | 包含非那雄胺的缓释型注射用组合物 | |
Lu et al. | Multifunctional inverse opal microneedle arrays for drug delivery and monitoring | |
Sun et al. | Preparation and characterization of tacrolimus-loaded SLNs in situ gel for ocular drug delivery for the treatment of immune conjunctivitis | |
CN103356491A (zh) | 一种丁香苦苷plga纳米粒的制备方法 | |
Madhavi et al. | Formulation and evaluation of Phenytoin sodium sustained release matrix tablet | |
Choi et al. | Long-acting injectable donepezil microspheres: Formulation development and evaluation | |
Nerkar et al. | Oromucosal delivery of venlafaxine by linseed mucilage based gel: In vitro and in vivo evaluation in rabbits | |
Manna et al. | Pharmacokinetics and toxicity evaluation of a PLGA and chitosan-based micro-implant for sustained release of methotrexate in rabbit vitreous | |
Kim et al. | Effect of dispersion medium on pharmacokinetic profile of rotigotine crystalline suspension following Subcutaneous injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: FUZHOU GENERAL HOSPITAL OF NANJING MILITARY COMMAN Free format text: FORMER OWNER: WANG LIPING Effective date: 20150708 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150708 Address after: 350000 No. 156 West Second Ring Road, Gulou District, Fujian, Fuzhou Applicant after: Fuzhou General Hospital, Nanjing Military Command, PLA. Address before: 350000 Fuzhou General Hospital of Nanjing military area, No. 156 West Second Ring Road, Gulou District, Fujian, Fuzhou Applicant before: Wang Liping |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |